Alkermes plc. (ALKS)
About Alkermes plc.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $1.5B
- Net income
- $241.7M
- Total assets
- $2.5B
- Market cap
- $8.8B
- Gross margin
- 86.7%
- Operating margin
- 17.2%
- Net margin
- 16.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.5B
- Cost of revenue
- $196.5M
- Gross profit
- $1.3B
- Operating expenses
- $1.0B
- Operating income
- $254.0M
- Income tax
- $49.8M
- Net income
- $241.7M
- EPS (basic)
- $1.47
- EPS (diluted)
- $1.43
Balance sheet
- Total assets
- $2.5B
- Current assets
- $1.9B
- Total liabilities
- $667.7M
- Current liabilities
- $543.4M
- Shareholders’ equity
- $1.8B
Cash flow
- Operating cash flow
- $520.8M
- Investing cash flow
- $295.5M
- Financing cash flow
- $12.4M
- Net cash flow
- $828.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $8.8B
- P/E ratio
- 34.5
- EPS (diluted)
- $1.43
- Shares outstanding
- 178.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 16, 1991
Alkermes plc. (ALKS) Stock Price
- Profitable — net income of $241.7M in FY2025.
- Revenue grew 26% from FY2021 to FY2025.
- Gross margin of 86.7%, net margin 16.4%.
- Trading 11% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 34.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Alkermes plc..
Write a review
News about Alkermes plc.
News & sentiment via Polygon.io
Alkermes plc.: frequently asked questions
Is Alkermes plc. an American company?
Alkermes plc. is a US-based company headquartered in Dublin 4, L2, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Alkermes plc. headquartered?
Alkermes plc. is headquartered in Dublin 4, L2, United States.
Is Alkermes plc. publicly traded?
Yes — Alkermes plc. is a publicly traded company. Its stock trades under the ticker symbol ALKS on the NASDAQ.
What does Alkermes plc. do?
Alkermes plc. is an American Pharmaceuticals company in the Health & Beauty sector.
